ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2013
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Trial
- Predictors of secondary progressive multiple sclerosis in a real word retrospective cohort: the role of clinical factors and disease-modifying therapy patterns.Acta neurologica Belgica · 2026Article
- Predictors of risk of secondary progression in multiple sclerosis.Therapeutic advances in neurological disorders · 2025Article
- Temporal trends of epilepsy in multiple sclerosis.Acta neurologica Scandinavica · 2022Article
- Smouldering multiple sclerosis: the 'real MS'.Therapeutic advances in neurological disorders · 2022Review
- The need for a strategic therapeutic approach: multiple sclerosis in check.Therapeutic advances in chronic disease · 2022Review
- Apparent changes in the epidemiology and severity of multiple sclerosis.Nature reviews. Neurology · 2021Review
- A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.Journal of neurology · 2021Review
- Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.Patient preference and adherence · 2021Article
- Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.Multiple sclerosis and related disorders · 2021Article
- State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis.Neurology and therapy · 2020Review
- CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020Observational
- Should We Use Clinical Tools to Identify Disease Progression?Frontiers in neurology · 2020Review
- Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.Neurology and therapy · 2019Article
- Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.Medicina (Kaunas, Lithuania) · 2019Article
- Observational
- Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes.Frontiers in neurology · 2019Review
- Pediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients.Neuropsychiatric disease and treatment · 2018Article
- Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis.Frontiers in neurology · 2018Article
- Treatment decisions in multiple sclerosis - insights from real-world observational studies.Nature reviews. Neurology · 2017Review
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is currently unknown whether early immunomodulatory treatment in relapsing-remitting MS (RRMS) can delay the transition to secondary progression (SP).
objectiveTo compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first generation disease modifying drugs (DMDs), and a historical control cohort.
methodsWe included a cohort of contemporary RRMS patients treated with DMDs, obtained from the Swedish National MS Registry (disease onset between 1995-2004, n = 730) and a historical population-based incidence cohort (onset 1950-64, n = 186). We retrospectively analyzed the difference in time to SP, termed the "period effect" within a 12-year survival analysis, using Kaplan-Meier and Cox regression analysis.
resultsWe found that the "period" affected the entire severity spectrum. After adjusting for onset features, which were weaker in the contemporary material, as well as the therapy initiation time, the DMD-treated patients still exhibited a longer time to SP than the controls (hazard ratios: men, 0.32; women, 0.53).
conclusionOur results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.